This technology uses deep ultraviolet Raman spectroscopy and advanced data analysis to quickly and non-destructively measure how much mRNA is unencapsulated in lipid nanoparticles, improving quality control for mRNA vaccines and therapeutics without chemical labels.
Background: Messenger RNA (mRNA) therapeutics, particularly those delivered via lipid nanoparticles (LNPs), have become a cornerstone of modern vaccine and drug development, as exemplified by the rapid deployment of mRNA vaccines during the COVID-19 pandemic. The encapsulation of mRNA within LNPs is critical for protecting the genetic material from degradation, enhancing cellular uptake, and ensuring efficient delivery to target cells. As the field of RNA-based medicines expands, there is a growing need for robust analytical tools that can accurately assess the encapsulation efficiency of mRNA within these nanoparticles. Such tools are essential for quality control, formulation optimization, and regulatory compliance in the manufacturing of mRNA therapeutics. Current methods for quantifying unencapsulated mRNA in LNP formulations face significant limitations. Many rely on indirect, destructive, or label-dependent techniques, such as fluorescence-based assays or chemical extraction, which can compromise sample integrity and introduce variability. These approaches often lack the sensitivity or specificity needed to distinguish between fully encapsulated, partially encapsulated, and free mRNA, making it difficult to precisely evaluate formulation quality. Additionally, autofluorescence from lipid components and the need for chemical labels can obscure analytical results, while destructive sample preparation precludes real-time or high-throughput analysis. As a result, there remains a critical unmet need for rapid, non-destructive, and label-free analytical methods that can provide accurate, molecular-level insights into mRNA encapsulation within LNPs.
Technology Overview: This technology provides a non-destructive, label-free analytical method for quantifying unencapsulated mRNA within lipid nanoparticles (LNPs), which are widely used in mRNA vaccines and therapeutics. Leveraging deep ultraviolet resonance Raman spectroscopy (DUVRRS), the method eliminates autofluorescence and significantly enhances the vibrational signals of mRNA. Principal component analysis (PCA) is then used to classify the encapsulation state of mRNA—distinguishing between fully encapsulated, partially encapsulated, and free mRNA—by identifying changes in key spectral features. Correlation spectroscopy further quantifies the amount of free mRNA. This solution is differentiated by its integration of deep-UV Raman spectroscopy with advanced chemometric techniques, enabling rapid, label-free, and non-destructive quantification of mRNA encapsulation. Unlike conventional methods that may require chemical labeling, destructive sample preparation, or lack sensitivity, this approach provides molecular-level insights without altering the sample. Our approach offers quantitative precision, making the method suitable for quality control, formulation screening, and process development in pharmaceutical manufacturing. Its scalability, robustness, and ability to provide both qualitative and quantitative metrics set it apart as a critical tool for advancing the quality and efficiency of mRNA-based therapeutics and vaccines.
https://suny.technologypublisher.com/files/sites/adobestock_404350568.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Non-destructive and label-free quantification of unencapsulated mRNA in lipid nanoparticles • Elimination of autofluorescence and enhanced mRNA signal detection using deep-UV excitation • Robust classification of mRNA encapsulation states through principal component analysis (PCA) • Quantitative estimation of free mRNA • Improved quality control and formulation screening for mRNA vaccines and therapeutics • Scalable and rapid analytical workflow suitable for pharmaceutical manufacturing and regulatory use • Enables molecular-level assessment without chemical modification or sample destruction
Applications: • mRNA vaccine quality control • Therapeutic formulation screening • Regulatory analytical standardization • Nucleic acid delivery system assessment
Intellectual Property Summary: Patent application filed
Stage of Development: TRL 3
Licensing Status: This technology is available for licensing.